Using Flow Electroporation to Find More Relevant Candidates and Shorten the Antibody Development Timeline

As the number of biotherapeutics grows, success in the coming years will depend on the ability to get to market quickly. This will involve the ability to work upstream in the manufacturing cell line. While transient gene expression is a rapid and cost-effective means of protein production, particularly during early development and preclinical stages, most transient transfection methods do not meet the requirements of scalability, consistency, speed, and cell type flexibility.

Read More

Strategies for Improved Protein Expression, Production Timelines and Laboratory Productivity Using CHO Cell Transient Expression.

Although protein biotherapeutics continue to have clinical success, companies are challenged to produce new clinical candidates with fewer resources and shortened timelines. Maximizing transient protein production and laboratory productivity play central roles in meeting those challenges, both of which rely on high performance, flexible CHO cell transfection for implementation.

Read More